|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal Susitarimą)
| (51) | INT.CL. | A61K 38/36 | |
| A61P 9/10 |
| (11) | Patento numeris | 1200116 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 00943706.2 |
| Europos patento paraiškos padavimo data | 2000-07-14 | |
| (97) | Europos patento paraiškos paskelbimo data | 2002-05-02 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2008-10-15 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/DK2000/000401 |
| Data | 2000-07-14 |
| (87) | Numeris | WO 2001/005353 |
| Data | 2001-01-25 |
| (30) | Numeris | Data | Šalis |
| 102399 | 1999-07-14 | DK | |
| 111799 | 1999-08-12 | DK |
| (72) |
EZBAN, Mirella, DK
PETERSEN, Lars, Christian, DK
SIEGBAHN, Agneta, SE
|
| (73) |
Novo Nordisk Health Care AG,
Andreasstrasse 15, 8050 Zürich,
CH
|
| (54) | USE OF FVIIa OR A TISSUE FACTOR AGONIST FOR REGULATING GENE EXPRESSION AND CELL MIGRATION OR CHEMOTAXIS |
| USE OF FVIIa OR A TISSUE FACTOR AGONIST FOR REGULATING GENE EXPRESSION AND CELL MIGRATION OR CHEMOTAXIS |